Akebia Therapeutics Inc (AKBA)
1.37
+0.07
(+5.38%)
USD |
NASDAQ |
May 03, 16:00
1.42
+0.05
(+3.65%)
Pre-Market: 20:00
Akebia Therapeutics Free Cash Flow: -23.38M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| December 31, 2023 | -23.38M |
| September 30, 2023 | -75.76M |
| June 30, 2023 | -34.78M |
| March 31, 2023 | -69.07M |
| December 31, 2022 | -73.27M |
| September 30, 2022 | -81.40M |
| June 30, 2022 | -171.47M |
| March 31, 2022 | -203.95M |
| December 31, 2021 | -253.02M |
| September 30, 2021 | -221.32M |
| June 30, 2021 | -192.24M |
| March 31, 2021 | -91.92M |
| December 31, 2020 | -110.70M |
| September 30, 2020 | -171.96M |
| June 30, 2020 | -136.31M |
| March 31, 2020 | -213.83M |
| December 31, 2019 | -264.10M |
| September 30, 2019 | -246.27M |
| June 30, 2019 | -267.50M |
| March 31, 2019 | -218.33M |
| December 31, 2018 | -99.10M |
| Date | Value |
|---|---|
| September 30, 2018 | -41.40M |
| June 30, 2018 | -83.84M |
| March 31, 2018 | -68.45M |
| December 31, 2017 | -57.78M |
| September 30, 2017 | 54.67M |
| June 30, 2017 | 80.38M |
| March 31, 2017 | 27.96M |
| December 31, 2016 | 55.24M |
| September 30, 2016 | -63.36M |
| June 30, 2016 | -43.01M |
| March 31, 2016 | -26.95M |
| December 31, 2015 | -52.82M |
| September 30, 2015 | -39.06M |
| June 30, 2015 | -35.56M |
| March 31, 2015 | -30.11M |
| December 31, 2014 | -27.71M |
| September 30, 2014 | -23.41M |
| June 30, 2014 | -20.71M |
| March 31, 2014 | -15.81M |
| December 31, 2013 | -11.33M |
Free Cash Flow Range, Past 5 Years
-267.50M
Minimum
Jun 2019
-23.38M
Maximum
Dec 2023
-152.75M
Average
-171.47M
Median
Jun 2022
Free Cash Flow Benchmarks
| Ocugen Inc | -72.53M |
| Aquestive Therapeutics Inc | -7.375M |
| SELLAS Life Sciences Group Inc | -36.91M |
| Protagonist Therapeutics Inc | -70.84M |
| Stoke Therapeutics Inc | -82.68M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -2.308M |
| Cash from Financing (Quarterly) | -1.29M |
| Free Cash Flow Per Share (Quarterly) | -0.0122 |
| Free Cash Flow to Equity (Quarterly) | 5.622M |
| Free Cash Flow Yield | -9.11% |